{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:11:42Z","timestamp":1790136702351,"version":"4.0.1"},"reference-count":17,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"Suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec><jats:title>Object<\/jats:title><jats:p>The aim of this study was to evaluate long-term clinical outcomes after Gamma Knife surgery (GKS) for patients with neurofibromatosis Type 2 (NF2) and the role of GKS in the management of NF2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From December 1994 through December 2008, a total of 46 patients (21 male, 25 female) with NF2 underwent GKS and follow-up evaluation for at least 5 years at the Gamma Knife Center of the Beijing Neurosurgical Institute. GKS was performed using the Leksell Gamma Knife Models B and C. The mean age of the patients was 30 years (range 13\u201359 years). A family history of NF2 was found for 9 (20%) patients. The NF2 phenotype was thought to be Wishart for 20 (44%) and Feiling-Gardner for 26 (56%) patients. Among these 46 patients, GKS was performed to treat 195 tumors (73 vestibular schwannomas and 122 other tumors including other schwannomas and meningiomas). For vestibular schwannomas, the mean volume was 5.1 cm<jats:sup>3<\/jats:sup> (median 3.6 cm<jats:sup>3<\/jats:sup>, range 0.3\u201327.3 cm<jats:sup>3<\/jats:sup>), the mean margin dose was 12.9 Gy (range 10\u201314 Gy), and the mean maximum dose was 27.3 Gy (range 16.2\u201340 Gy). For other tumors, the mean volume was 1.7 cm<jats:sup>3<\/jats:sup> (range 0.3\u20135.5 cm<jats:sup>3<\/jats:sup>), the mean margin dose was 13.3 Gy (range 11\u201314 Gy), and the mean maximum dose was 26.0 Gy (range 18.0\u201330.4 Gy). The median duration of follow-up was 109 months (range 8\u2013195 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For the 73 vestibular schwannomas that underwent GKS, the latest follow-up MR images demonstrated regression of 30 (41%) tumors, stable size for 31 (43%) tumors, and enlargement of 12 (16%) tumors. The total rate of tumor control for bilateral vestibular schwannomas in patients with NF2 was 84%. Of the 122 other types of tumors that underwent GKS, 103 (85%) showed no tumor enlargement. The rate of serviceable hearing preservation after GKS was 31.9% (15\/47). The actuarial rates for hearing preservation at 3 years, 5 years, 10 years, and 15 years were 98%, 93%, 44%, and 17%, respectively. Of the 46 patients, 22 (48%) became completely bilaterally deaf, 17 (37%) retained unilateral serviceable hearing, and 7 (15%) retained bilateral serviceable hearing. The mean history of the disease course was 12 years (range 5\u201338 years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>GKS was confirmed to provide long-term local tumor control for small- to medium-sized vestibular schwannomas and other types of tumors, although vestibular schwannomas in patients with NF2 responded less well than did unilateral sporadic vestibular schwannomas. Phenotype is the most strongly predictive factor of final outcome after GKS for patients with NF2. The risk for loss of hearing is high, whereas the risk for other cranial nerve complications is low.<\/jats:p><\/jats:sec>","DOI":"10.3171\/2014.8.gks141503","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:56:53Z","timestamp":1542365813000},"page":"143-149","source":"Crossref","is-referenced-by-count":32,"title":["Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2"],"prefix":"10.3171","volume":"121","author":[{"given":"Shibin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-14-1503","series-title":"J Med Genet","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/jmg.2004.029504","article-title":"The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2","volume":"42","author":"Baser","year":"2005"},{"key":"b2-14-1503","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3171\/jns.2002.96.2.0217","article-title":"Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2","volume":"96","author":"Baser","year":"2002"},{"key":"b3-14-1503","series-title":"J Laryngol Otol","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy","volume":"126","author":"Eminowicz","year":"2012"},{"key":"b4-14-1503","series-title":"Br J Neurosurg","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","article-title":"Management of the patient and family with neurofibromatosis 2: a consensus conference statement","volume":"19","author":"Evans","year":"2005"},{"key":"b5-14-1503","series-title":"J Med Genet","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/jmg.29.12.847","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling","volume":"29","author":"Evans","year":"1992"},{"key":"b6-14-1503","series-title":"J Med Genet","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jmg.35.6.450","article-title":"Genotype\/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations","volume":"35","author":"Evans","year":"1998"},{"key":"b7-14-1503","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0090-3019(00)00174-9","article-title":"Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2","volume":"53","author":"Kida","year":"2000"},{"key":"b8-14-1503","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1227\/NEU.0000000000000264","article-title":"Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes","volume":"74","author":"Mallory","year":"2014"},{"key":"b9-14-1503","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1227\/01.NEU.0000255340.26027.53","article-title":"Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates","volume":"60","author":"Mathieu","year":"2007"},{"key":"b10-14-1503","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.24036","article-title":"Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation","volume":"115","author":"Phi","year":"2009"},{"key":"b11-14-1503","series-title":"Otol Neurotol","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012"},{"key":"b12-14-1503","series-title":"Neurochirurgie","first-page":"339","article-title":"[Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas]","volume":"46","author":"Roche","year":"2000"},{"key":"b13-14-1503","series-title":"Nature","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993"},{"key":"b14-14-1503","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/jnnp.74.9.1288","article-title":"Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis","volume":"74","author":"Rowe","year":"2003"},{"key":"b15-14-1503","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-010-0181-1","article-title":"Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2","volume":"98","author":"Sharma","year":"2010"},{"key":"b16-14-1503","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3171\/jns.1999.90.5.0815","article-title":"Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2","volume":"90","author":"Subach","year":"1999"},{"key":"b17-14-1503","series-title":"Cell","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/121\/Suppl_2\/article-p143.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/121\/Suppl_2\/article-p143.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/121\/Suppl_2\/article-p143.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:45:12Z","timestamp":1658709912000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/121\/Suppl_2\/article-p143.xml"}},"subtitle":["Clinical article"],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":17,"journal-issue":{"issue":"Suppl_2"},"URL":"https:\/\/doi.org\/10.3171\/2014.8.gks141503","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}